CYTOSORBENTS CORPORATION Earnings Per Share (Basic)
CYTOSORBENTS CORPORATION (CTSO) reported Earnings Per Share (Basic) of -$0.07 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- CYTOSORBENTS CORPORATION earnings per share, basic for the quarter ending 2026-06-30 was -$0.07, a 333.33% decline year-over-year.
- CYTOSORBENTS CORPORATION earnings per share, basic for the quarter ending 2026-03-31 was -$0.08.
- CYTOSORBENTS CORPORATION earnings per share, basic for the quarter ending 2025-12-31 was -$0.09.
- CYTOSORBENTS CORPORATION earnings per share, basic for the quarter ending 2025-09-30 was -$0.05.
- CYTOSORBENTS CORPORATION earnings per share, basic for fiscal 2025 was -$0.13.
- CYTOSORBENTS CORPORATION earnings per share, basic for fiscal 2024 was -$0.38.
- CYTOSORBENTS CORPORATION earnings per share, basic for fiscal 2023 was -$0.65.
- CYTOSORBENTS CORPORATION earnings per share, basic for fiscal 2022 was -$0.75.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.07 10-Q · filed 2026-08-06 | -$0.15 10-Q · filed 2026-08-06 | -$0.24 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-08-06 | |||
| 2026-03-31 | -$0.08 10-Q · filed 2026-05-13 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-05-13 | -$0.22 derived: net income ÷ weighted average shares · filed 2026-05-13 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-08-06 | |||
| 2025-12-31 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$0.14 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$0.11 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.13 10-K · filed 2026-03-30 | |||
| 2025-09-30 | -$0.05 10-Q · filed 2025-11-13 | -$0.02 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.04 10-Q · filed 2025-11-13 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-08-06 | |||
| 2025-06-30 | $0.03 10-Q · filed 2026-08-06 | $0.01 10-Q · filed 2026-08-06 | -$0.12 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-08-06 | |||
| 2025-03-31 | -$0.02 10-Q · filed 2026-05-13 | -$0.16 derived: net income ÷ weighted average shares · filed 2026-05-13 | -$0.21 derived: net income ÷ weighted average shares · filed 2026-05-13 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-05-13 | |||
| 2024-12-31 | -$0.14 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$0.27 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$0.38 10-K · filed 2026-03-30 | |||
| 2024-09-30 | -$0.05 10-Q · filed 2025-11-13 | -$0.04 10-Q · filed 2024-11-07 | -$0.13 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$0.24 10-Q · filed 2025-11-13 | -$0.37 derived: net income ÷ weighted average shares · filed 2025-11-13 | ||
| 2024-06-30 | -$0.08 10-Q · filed 2025-08-07 | -$0.19 10-Q · filed 2025-08-07 | -$0.32 derived: net income ÷ weighted average shares · filed 2025-08-07 | -$0.51 derived: net income ÷ weighted average shares · filed 2025-08-07 | |||
| 2024-03-31 | -$0.11 10-Q · filed 2025-05-14 | -$0.12 10-Q · filed 2024-05-09 | -$0.24 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$0.44 derived: net income ÷ weighted average shares · filed 2025-05-14 | -$0.58 derived: net income ÷ weighted average shares · filed 2025-05-14 | ||
| 2023-12-31 | -$0.12 10-K · filed 2024-03-15 | -$0.33 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$0.47 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$0.65 10-K · filed 2025-03-31 | -$0.64 10-K · filed 2024-03-15 | ||
| 2023-09-30 | -$0.21 10-K · filed 2025-03-31 | -$0.35 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$0.52 10-K · filed 2025-03-31 | -$0.53 derived: net income ÷ weighted average shares · filed 2024-11-07 | |||
| 2023-06-30 | -$0.15 10-K · filed 2025-03-31 | -$0.14 10-Q · filed 2023-08-01 | -$0.32 10-K · filed 2025-03-31 | -$0.31 10-Q · filed 2023-08-01 | -$0.33 derived: net income ÷ weighted average shares · filed 2024-08-13 | -$0.60 derived: net income ÷ weighted average shares · filed 2024-08-13 | |
| 2023-03-31 | -$0.17 10-K · filed 2025-03-31 | -$0.19 derived: net income ÷ weighted average shares · filed 2024-05-09 | -$0.47 derived: net income ÷ weighted average shares · filed 2024-05-09 | -$0.71 derived: net income ÷ weighted average shares · filed 2024-05-09 | |||
| 2022-12-31 | -$0.02 10-K · filed 2024-03-15 | -$0.30 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.55 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.75 10-K · filed 2024-03-15 | |||
| 2022-09-30 | -$0.28 10-K · filed 2024-03-15 | -$0.53 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.74 10-Q · filed 2023-11-09 | -$0.95 derived: net income ÷ weighted average shares · filed 2024-03-15 | |||
| 2022-06-30 | -$0.25 10-K · filed 2024-03-15 | -$0.46 10-Q · filed 2023-08-01 | -$0.67 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.82 derived: net income ÷ weighted average shares · filed 2024-03-15 | |||
| 2022-03-31 | -$0.21 10-K · filed 2024-03-15 | -$0.42 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.57 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.68 derived: net income ÷ weighted average shares · filed 2024-03-15 | |||
| 2021-12-31 | -$0.25 10-K · filed 2024-03-15 | -$0.36 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.47 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.57 10-K · filed 2024-03-15 | |||
| 2021-09-30 | -$0.15 10-K · filed 2024-03-15 | -$0.26 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.35 10-Q · filed 2022-11-03 | -$0.37 derived: net income ÷ weighted average shares · filed 2024-03-15 | |||
| 2021-06-30 | -$0.11 10-K · filed 2024-03-15 | -$0.20 10-Q · filed 2022-08-02 | -$0.22 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.24 derived: net income ÷ weighted average shares · filed 2024-03-15 | |||
| 2021-03-31 | -$0.10 10-K · filed 2024-03-15 | -$0.11 derived: net income ÷ weighted average shares · filed 2024-03-15 | -$0.13 derived: net income ÷ weighted average shares · filed 2024-03-15 | ||||
| 2020-12-31 | $0.00 10-K · filed 2023-03-09 | -$0.04 derived: net income ÷ weighted average shares · filed 2023-03-09 | -$0.20 10-K · filed 2023-03-09 | ||||
| 2020-09-30 | -$0.02 10-K · filed 2023-03-09 | -$0.19 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | -$0.08 10-K · filed 2023-03-09 | ||||||
| 2020-03-31 | -$0.10 10-K · filed 2023-03-09 | ||||||
| 2019-12-31 | -$0.13 10-K · filed 2022-03-10 | -$0.60 10-K · filed 2022-03-10 | |||||
| 2019-09-30 | -$0.21 10-K · filed 2022-03-10 | ||||||
| 2019-06-30 | -$0.11 10-K · filed 2022-03-10 | ||||||
| 2019-03-31 | -$0.15 10-K · filed 2022-03-10 | ||||||
| 2016-06-30 | -$0.12 10-Q · filed 2016-08-09 | -$0.19 10-Q · filed 2016-08-09 | |||||
| 2015-12-31 | -$0.08 10-K · filed 2017-03-03 | ||||||
| 2015-09-30 | -$0.11 10-K · filed 2017-03-03 | ||||||
| 2015-06-30 | $0.06 10-K · filed 2017-03-03 | -$0.13 10-Q · filed 2016-08-09 | |||||
| 2015-03-31 | -$0.19 10-K · filed 2017-03-03 | ||||||
| 2014-06-30 | -$0.27 10-Q · filed 2015-08-13 | -$0.47 10-Q · filed 2015-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |